{"id":"ub-421","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Immune activation syndrome"},{"rate":null,"effect":"Lymphocyte count changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"UB-421 binds to the CD4 receptor on the surface of T cells, which is the primary entry point for HIV. By occupying this receptor, the antibody prevents HIV from attaching to and infecting CD4+ T cells. This mechanism aims to reduce viral load and preserve immune function in people living with HIV.","oneSentence":"UB-421 is a monoclonal antibody that targets and blocks CD4 on T cells to modulate immune function in HIV infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:58.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (in combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT05582694","phase":"PHASE2","title":"A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-10","conditions":"Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection","enrollment":""},{"nctId":"NCT04985890","phase":"PHASE2","title":"A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir","status":"NOT_YET_RECRUITING","sponsor":"UBP Greater China (Shanghai) Co., Ltd","startDate":"2024-03","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT03149211","phase":"PHASE3","title":"To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults","status":"WITHDRAWN","sponsor":"United BioPharma","startDate":"2025-04-01","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT04620304","phase":"PHASE1","title":"Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients","status":"COMPLETED","sponsor":"United BioPharma","startDate":"2021-01-01","conditions":"HIV-1 Infection","enrollment":15},{"nctId":"NCT03164447","phase":"PHASE2","title":"UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients","status":"UNKNOWN","sponsor":"United BioPharma","startDate":"2023-12","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT04406727","phase":"PHASE3","title":"UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"United BioPharma","startDate":"2023-12-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT05056974","phase":"PHASE2","title":"A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs","status":"COMPLETED","sponsor":"United BioPharma","startDate":"2021-12-02","conditions":"HIV-1 Infection","enrollment":11},{"nctId":"NCT04404049","phase":"PHASE2","title":"The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients","status":"UNKNOWN","sponsor":"UBP Greater China (Shanghai) Co., Ltd","startDate":"2023-12-01","conditions":"HIV-1-infection","enrollment":39},{"nctId":"NCT03743376","phase":"PHASE2","title":"The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients","status":"COMPLETED","sponsor":"United BioPharma","startDate":"2018-12-12","conditions":"HIV-1 Infection","enrollment":31},{"nctId":"NCT04620291","phase":"PHASE1","title":"Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults","status":"UNKNOWN","sponsor":"United BioPharma","startDate":"2023-12-31","conditions":"HIV-1-infection","enrollment":18},{"nctId":"NCT04041362","phase":"PHASE2","title":"the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients","status":"WITHDRAWN","sponsor":"United BioPharma","startDate":"2020-04","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT02369146","phase":"PHASE2","title":"To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults","status":"COMPLETED","sponsor":"United BioPharma","startDate":"2015-06","conditions":"HIV-1 Infection","enrollment":29},{"nctId":"NCT01668043","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults","status":"COMPLETED","sponsor":"United Biomedical","startDate":"2012-09","conditions":"HIV-1 Infection in Adults","enrollment":29},{"nctId":"NCT01140126","phase":"PHASE1","title":"Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults","status":"COMPLETED","sponsor":"United Biomedical","startDate":"2010-05","conditions":"HIV-1 Infection in Adults (Asymptomatic)","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dB4C7 mAb"],"phase":"phase_3","status":"active","brandName":"UB-421","genericName":"UB-421","companyName":"United BioPharma","companyId":"united-biopharma","modality":"Biologic","firstApprovalDate":"","aiSummary":"UB-421 is a monoclonal antibody that targets and blocks CD4 on T cells to modulate immune function in HIV infection. Used for HIV-1 infection (in combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}